TrialScientific reports2025

Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma.

Mingfang Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.